中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2306-2314

Systemic therapy for advanced hepatocellular carcinoma

DOI: 10.12449/JCH241127
  • 1.

    Department of Hepatobiliary Surgery，Eastern Hepatobiliary Surgery Hospital，The Third Affiliated Hospital of Navy Medical University，Shanghai 200438，China

  • 2.

    School of Public Health，Hangzhou Medical College，Hangzhou 310063，China

  • 3.

    School of Basic Medical Sciences，Bengbu Medical University，Bengbu，Anhui 233000，China

Research funding:

National Natural Science Foundation of China (81972726);

Natural Science Foundation of Shanghai (22ZR1477900)

More Information
  • Corresponding author: YANG Tian， yangtian6666@hotmail.com （ORCID： 0000-0003-1544-0976）
  • Received Date: 2024-03-31
  • Accepted Date: 2024-05-30
  • Published Date: 2024-11-25
    Abstract
  • Hepatocellular carcinoma （HCC） is one of the most common malignancies with high morbidity and mortality rates worldwide. With the advances in molecular biology and tumor immunology， molecular-targeted agents represented by tyrosine kinase inhibitors （such as sorafenib and lenvatinib） and immunotherapy represented by PD-1/PD-L1 monoclonal antibodies have brought hope for patients with advanced HCC. The combination of immunotherapy and anti-angiogenic therapy can further improve the treatment outcome of patients. In addition， the optimization and integration of stereotactic body radiotherapy， local treatment， and systemic treatment may maximize the benefits of patients. In the future， through a deep understanding of the heterogeneity of HCC， the development of precision molecular subtyping and individualized treatment， and the establishment of a multidisciplinary collaborative diagnosis and treatment system， systemic therapy is expected to achieve long-term management of advanced HCC. This article reviews the current status and advances in systemic therapy for advanced HCC.

     

    • FullText(HTML)
  • loading
    • References(48)
  • [1]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [2]
    YANG T, WANG MD, XU XF, et al. Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences[J]. Clin Mol Hepatol, 2023, 29( 2): 342- 344. DOI: 10.3350/cmh.2023.0106.
    [3]
    YANG T, ZHANG H, LAU WY, et al. Liver disease in China: A long way to go[J]. Hepatology, 2015, 62( 5): 1640. DOI: 10.1002/hep.27769.
    [4]
    VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380( 15): 1450- 1462. DOI: 10.1056/nejmra1713263.
    [5]
    WANG MD, DIAO YK, YAO LQ, et al. Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma[J]. iLIVER, 2024, 3( 1): 100083. DOI: 10.1016/j.iliver.2024.100083.
    [6]
    YANG C, ZHANG HL, ZHANG LM, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 4): 203- 222. DOI: 10.1038/s41575-022-00704-9.
    [7]
    ZHU AX, DUDA DG, SAHANI DV, et al. HCC and angiogenesis: Possible targets and future directions[J]. Nat Rev Clin Oncol, 2011, 8( 5): 292- 301. DOI: 10.1038/nrclinonc.2011.30.
    [8]
    LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359( 4): 378- 390. DOI: 10.1056/NEJMoa0708857.
    [9]
    CHENG AL, KANG YK, CHEN ZD, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10( 1): 25- 34. DOI: 10.1016/S1470-2045(08)70285-7.
    [10]
    KUDO M, FINN RS, QIN SK, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [11]
    ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379( 1): 54- 63. DOI: 10.1056/NEJMoa1717002.
    [12]
    BRUIX J, QIN SK, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389( 10064): 56- 66. DOI: 10.1016/S0140-6736(16)32453-9.
    [13]
    QIN SK, LI Q, GU SZ, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma(AHELP): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6( 7): 559- 568. DOI: 10.1016/S2468-1253(21)00109-6.
    [14]
    QIN SK, BI F, GU SZ, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: A randomized, open-label, parallel-controlled phase II-III trial[J]. J Clin Oncol, 2021, 39( 27): 3002- 3011. DOI: 10.1200/JCO.21.00163.
    [15]
    PINTER M, SCHEINER B, PECK-RADOSAVLJEVIC M. Immunotherapy for advanced hepatocellular carcinoma: A focus on special subgroups[J]. Gut, 2021, 70( 1): 204- 214. DOI: 10.1136/gutjnl-2020-321702.
    [16]
    LLOVET JM, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15( 10): 599- 616. DOI: 10.1038/s41571-018-0073-4.
    [17]
    EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389( 10088): 2492- 2502. DOI: 10.1016/S0140-6736(17)31046-2.
    [18]
    KUDO M, MATILLA A, SANTORO A, et al. Checkmate-040: Nivolumab(NIVO) in patients(pts) with advanced hepatocellular carcinoma(aHCC) and Child-Pugh B(CPB) status[J]. J Clin Oncol, 2019, 37( 4_suppl): 327. DOI: 10.1200/jco.2019.37.4_suppl.327.
    [19]
    QIN SK, KUDO M, MEYER T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A phase 3 randomized clinical trial[J]. JAMA Oncol, 2023, 9( 12): 1651- 1659. DOI: 10.1001/jamaoncol.2023.4003.
    [20]
    ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19( 7): 940- 952. DOI: 10.1016/S1470-2045(18)30351-6.
    [21]
    FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab As second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial[J]. J Clin Oncol, 2020, 38( 3): 193- 202. DOI: 10.1200/JCO.19.01307.
    [22]
    QIN SK, CHEN ZD, LIU Y, et al. A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer[J]. J Clin Oncol, 2019, 37( 15_suppl): 4074. DOI: 10.1200/jco.2019.37.15_suppl.4074.
    [23]
    FINN RS, IKEDA M, ZHU AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38( 26): 2960- 2970. DOI: 10.1200/JCO.20.00808.
    [24]
    FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [25]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [26]
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology(NCCN Guidelines). Hepatocellular carcinoma. Version 2. 2024[EB/OL]. https://www.nccn.org/login?ReturnURL=tts://www.nccn.org/professionals/physician%20gls/pdf/hcc.pdf. https://www.nccn.org/login?ReturnURL=tts://www.nccn.org/professionals/physician%20gls/pdf/hcc.pdf
    [27]
    SINGAL AG, LLOVET JM, YARCHOAN M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78( 6): 1922- 1965. DOI: 10.1097/HEP.0000000000000466.
    [28]
    HUANG DX, CHEN Y, ZENG QL, et al. Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration[J]. Oncol Lett, 2018, 15( 3): 3383- 3389. DOI: 10.3892/ol.2018.7844.
    [29]
    REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
    [30]
    QIN SK, CHAN SL, GU SZ, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma(CARES-310): A randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402( 10408): 1133- 1146. DOI: 10.1016/S0140-6736(23)00961-3.
    [31]
    LLOVET JM, KUDO M, MERLE P, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma(LEAP-002): A randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24( 12): 1399- 1410. DOI: 10.1016/S1470-2045(23)00469-2.
    [32]
    QIN SK, XUR R, PAN HM, et al. First-line lenvatinib±pembrolizumab for advanced hepatocellular carcinoma: LEAP-002 China subgroup. APASL 2024, Abstr 100797[EB/OL]. https://www.apasl2024kyoto.org/docs/info/Accepted_Regular_Abstracts-APASL_2024_Kyoto-as_of_2023_12_18.pdf. https://www.apasl2024kyoto.org/docs/info/Accepted_Regular_Abstracts-APASL_2024_Kyoto-as_of_2023_12_18.pdf
    [33]
    KELLEY RK, RIMASSA L, CHENG AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23( 8): 995- 1008. DOI: 10.1016/S1470-2045(22)00326-6.
    [34]
    YAU T, KANG YK, KIM TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6( 11): e204564. DOI: 10.1001/jamaoncol.2020.4564.
    [35]
    GALLE PR, DECAENS T, KUDO M, et al. Nivolumab(NIVO) plus ipilimumab(IPI) vs lenvatinib(LEN) or sorafenib(SOR) as first-line treatment for unresectable hepatocellular carcinoma(uHCC): First results from CheckMate 9DW[J]. J Clin Oncol, 2024, 42( 17_suppl): LBA4008. DOI: 10.1200/JCO.2024.42.17_suppl.LBA4008.
    [36]
    KELLEY RK, SANGRO B, HARRIS W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study[J]. J Clin Oncol, 2021, 39( 27): 2991- 3001. DOI: 10.1200/JCO.20.03555.
    [37]
    ABOU-ALFA GK, LAU G, KUDO M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. NEJM Evid, 2022, 1( 8): EVIDoa2100070. DOI: 10.1056/EVIDoa2100070.
    [38]
    KUDO M, UESHIMA K, IKEDA M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69( 8): 1492- 1501. DOI: 10.1136/gutjnl-2019-318934.
    [39]
    PENG Z, FAN W, ZHU B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial(LAUNCH)[J]. J Clin Oncol, 2023, 41( 1): 117- 127. DOI: 10.1200/JCO.22.00392.
    [40]
    ZHAO M, LYU N, ZHONG S, et al. 983P Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis(Vp3/4)-the DurHope study[J]. Ann Oncol, 2023, 34: S608. DOI: 10.1016/j.annonc.2023.09.2128.
    [41]
    DAWSON LA, WINTER KA, KNOX JJ, et al. NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy(SBRT) followed by sorafenib in hepatocellular carcinoma(HCC)[J]. J Clin Oncol, 2023, 41( 4_suppl): 489. DOI: 10.1200/jco.2023.41.4_suppl.489.
    [42]
    YANG X, HU Y, YANG KY, et al. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9( 5): e001942. DOI: 10.1136/jitc-2020-001942.
    [43]
    ZAPPASODI R, WOLCHOK JD, MERGHOUB T. Strategies for predicting response to checkpoint inhibitors[J]. Curr Hematol Malig Rep, 2018, 13( 5): 383- 395. DOI: 10.1007/s11899-018-0471-9.
    [44]
    REN ZG, GUO YB, BAI YX, et al. Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study[J]. J Clin Oncol, 2023, 41( 4_suppl): 578. DOI: 10.1200/jco.2023.41.4_suppl.578.
    [45]
    XING BC, DA X, ZHANG YQ, et al. A phase II study combining KN046(an anti-PD-L1/CTLA-4 bispecific antibody) and lenvatinib in the treatment for advanced unresectable or metastatic hepatocellular carcinoma(HCC): Updated efficacy and safety results[J]. J Clin Oncol, 2022, 40( 16_suppl): 4115. DOI: 10.1200/jco.2022.40.16_suppl.4115.
    [46]
    FINN RS, RYOO BY, HSU CH, et al. Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab(tira) in combination with atezolizumab(atezo) and bevacizumab(bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma(uHCC)[J]. J Clin Oncol, 2023, 41( 16_suppl): 4010. DOI: 10.1200/jco.2023.41.16_suppl.4010.
    [47]
    REN Z, HUANG Y, GUO Y, et al. 945MO AdvanTIG-206: Phase II randomized open-label study of ociperlimab(OCI)+tislelizumab(TIS)+BAT1706(bevacizumab biosimilar) versus TIS+BAT1706 in patients(pts) with advanced hepatocellular carcinoma(HCC)[J]. Ann Oncol, 2023, 34: S594. DOI: 10.1016/j.annonc.2023.09.2091.
    [48]
    LU MY, WILLIAMSON DFK, CHEN TY, et al. Data-efficient and weakly supervised computational pathology on whole-slide images[J]. Nat Biomed Eng, 2021, 5( 6): 555- 570. DOI: 10.1038/s41551-020-00682-w.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (132) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return